Blood · 2005
Activating Notch1 mutations in mouse models of T-ALL.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
O'Neil Jennifer, Calvo Jennifer, McKenna Keith, Krishnamoorthy Veena, Aster Jon C, Bassing Craig H, Alt Frederick W, Kelliher Michelle, Look A Thomas
Аннотация
Recent studies have demonstrated that most patients with T-cell acute lymphocytic leukemia (T-ALL) have activating mutations in NOTCH1. We sought to determine whether these mutations are also acquired in mouse models of T-ALL. We sequenced the heterodimerization domain and the PEST domain of Notch1 in our mouse model of TAL1-induced leukemia and found that 74% of the tumors harbor activating mutations in Notch1. Cell lines derived from these tumors undergo G(0)/G(1) arrest and apoptosis when treated with a gamma-secretase inhibitor. In addition, we found activating Notch1 mutations in 31% of thymic lymphomas that occur in mice deficient for various combinations of the H2AX, Tp53, and Rag2 genes. Thus, Notch1 mutations are often acquired as a part of the molecular pathogenesis of T-ALLs that develop in mice with known predisposing genetic alterations.
Предметные рубрики MeSH
Amyloid Precursor Protein SecretasesAnimalsApoptosisAspartic Acid EndopeptidasesBasic Helix-Loop-Helix ProteinsDNA-Binding ProteinsDisease Models, AnimalEndopeptidasesEnzyme InhibitorsFemaleG1 PhaseHistonesHumansLeukemia-Lymphoma, Adult T-CellLymphomaMaleMiceMice, TransgenicMutationProto-Oncogene ProteinsReceptor, Notch1Resting Phase, Cell CycleT-Cell Acute Lymphocytic Leukemia Protein 1Thymus NeoplasmsTumor Suppressor Protein p53